Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo

Paromomycin is an aminoglycoside antibiotic approved in 2006 for the treatment of visceral leishmaniasis caused by Leishmania donovani in Southeast Asia. Although this drug is not approved for the treatment of visceral and cutaneous leishmaniasis in Brazil, it is urgent and necessary to evaluate the...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Elizabeth M. Coser, Bianca A. Ferreira, Nilson Branco, Edite H. Yamashiro-Kanashiro, José Angelo L. Lindoso, Adriano C. Coelho
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2020-12-01
Schriftenreihe:	International Journal for Parasitology: Drugs and Drug Resistance
Schlagworte:	Paromomycin Drug susceptibility Leishmaniasis Leishmania amazonensis
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S221132072030021X
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!